PharmiWeb.com - Global Pharma News & Resources

General - Press Releases

Date Title Company
06-Feb-2023 SDC Announces the Rollout of SDC Capture™ Solution Businesswire
06-Feb-2023 Anodyne Nanotech, Inc. Appoints Jeff Mihm to its Board of Directors Businesswire
06-Feb-2023 Nutcracker Therapeutics Adds Dr. Thomas J. Dietz to Board of Directors Businesswire
06-Feb-2023 Thompson Street Capital Partners Completes Growth Investment in Sabai Global Businesswire
06-Feb-2023 Concerto Biosciences Announces Strategic Business Development Hire Businesswire
06-Feb-2023 Oxford BioDynamics’ Prostate Screening EpiSwitch® Blood Test Significantly Enhances Overall Detection Accuracy For At Risk Men Businesswire
06-Feb-2023 GlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Businesswire
06-Feb-2023 TransMed7, LLC Announces First Clinical Cases of Concorde Soft Tissue Biopsy Devices for Commercial Launch Businesswire
06-Feb-2023 Silence Therapeutics Appoints J.P. Gabriel as Chief Technical Operations Officer Businesswire
06-Feb-2023 Pharma Veteran, Academician and Researcher Cristina Masseria, PhD, MSc to be Head of the Value and Evidence Team at AESARA Businesswire
06-Feb-2023 Sage Therapeutics and Biogen Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression Businesswire
06-Feb-2023 RBQM Market Leader, CluePoints, Celebrates Milestone of De-risking 1000 Clinical Studies CluePoints
06-Feb-2023 Profile of Sensoria Health: An Innovator in Wearable Medical Devices for Fitness and Health Care - ResearchAndMarkets.com Businesswire
06-Feb-2023 Slingshot Biosciences Announces $11 Million in Series A3 Financing Businesswire
06-Feb-2023 Data Integrity and Document Management Training Course: Latest MHRA Data Integrity Guide and EMA TMF Guidelines (April 21, 2023) - ResearchAndMarkets.com Businesswire
06-Feb-2023 First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s) Businesswire
05-Feb-2023 La FDA de EE. UU. aprueba TAKHZYRO® (lanadelumab-flyo) de Takeda para prevenir ataques de angioedema hereditario (AEH) en niños de 2 años en adelante Businesswire
05-Feb-2023 FDA dos EUA aprova TAKHZYRO® (lanadelumabe-flyo) da Takeda para prevenir crises de angioedema hereditário (HAE) em crianças com 2 anos de idade ou mais Businesswire
04-Feb-2023 Amerikanische Arzneimittelbehörde FDA genehmigt TAKHZYRO® (Lanadelumab-flyo) von Takeda zur Verhinderung von Attacken des hereditären Angioödems (HAE) bei Kindern im Alter ab 2 Jahren Businesswire
04-Feb-2023 Dentalis Animal Health appoints Advisory Board Businesswire